title: GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients.
abstract: Cytomegalovirus infection remains a major complication of solid organ transplantation. In 2005 the Spanish Transplantation Infection Study Group (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) developed consensus guidelines for the prevention and treatment of CMV infection in solid organ transplant recipients. Since then, numerous publications have clarified or questioned the aspects covered in the previous document. These aspects include the situations and populations who must receive prophylaxis and its duration, the selection of the best diagnosis and monitoring technique and the best therapeutic strategy. For these reasons, we have developed new consensus guidelines to include the latest recommendations on post-transplant CMV management based on new evidence available.
authors.affiliation: UGC Enfermedades Infecciosas, Hospital Universitario Reina Sofía-IMIBIC, Córdoba, Spain. julian.torre.sspa@juntadeandalucia.es
authors.forename: Julian
authors.initials: J
authors.lastname: de la Torre-Cisneros
authors.forename: M Carmen
authors.initials: MC
authors.lastname: Fariñas
authors.forename: Juan José
authors.initials: JJ
authors.lastname: Castón
authors.forename: José María
authors.initials: JM
authors.lastname: Aguado
authors.forename: Sara
authors.initials: S
authors.lastname: Cantisán
authors.forename: Jordi
authors.initials: J
authors.lastname: Carratalá
authors.forename: Carlos
authors.initials: C
authors.lastname: Cervera
authors.forename: José Miguel
authors.initials: JM
authors.lastname: Cisneros
authors.forename: Elisa
authors.initials: E
authors.lastname: Cordero
authors.forename: Maria G
authors.initials: MG
authors.lastname: Crespo-Leiro
authors.forename: Jesús
authors.initials: J
authors.lastname: Fortún
authors.forename: Esteban
authors.initials: E
authors.lastname: Frauca
authors.forename: Joan
authors.initials: J
authors.lastname: Gavaldá
authors.forename: Salvador
authors.initials: S
authors.lastname: Gil-Vernet
authors.forename: Mercé
authors.initials: M
authors.lastname: Gurguí
authors.forename: Oscar
authors.initials: O
authors.lastname: Len
authors.forename: Carlos
authors.initials: C
authors.lastname: Lumbreras
authors.forename: María Ángeles
authors.initials: MÁ
authors.lastname: Marcos
authors.forename: Pilar
authors.initials: P
authors.lastname: Martín-Dávila
authors.forename: Victor
authors.initials: V
authors.lastname: Monforte
authors.forename: Miguel
authors.initials: M
authors.lastname: Montejo
authors.forename: Asunción
authors.initials: A
authors.lastname: Moreno
authors.forename: Patricia
authors.initials: P
authors.lastname: Muñoz
authors.forename: David
authors.initials: D
authors.lastname: Navarro
authors.forename: Albert
authors.initials: A
authors.lastname: Pahissa
authors.forename: José Luis
authors.initials: JL
authors.lastname: Pérez
authors.forename: Alberto
authors.initials: A
authors.lastname: Rodriguez-Bernot
authors.forename: José
authors.initials: J
authors.lastname: Rumbao
authors.forename: Rafael
authors.initials: R
authors.lastname: San Juan
authors.forename: Francisco
authors.initials: F
authors.lastname: Santos
authors.forename: Evaristo
authors.initials: E
authors.lastname: Varo
authors.forename: Felipe
authors.initials: F
authors.lastname: Zurbano
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003587:Cytomegalovirus / Q000187:drug effects / Q000502:physiology; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control / Q000635:transmission; D019468:Disease Management; D046148:Donor Selection; D004334:Drug Administration Schedule; D024882:Drug Resistance, Viral; D019317:Evidence-Based Medicine; D006801:Humans; D007111:Immunity, Cellular; D016867:Immunocompromised Host; D012307:Risk Factors; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014019:Tissue Donors; D014180:Transplantation / Q000009:adverse effects; D014766:Viremia / Q000175:diagnosis; D014775:Virus Activation / Q000187:drug effects
chemical_list: D000998:Antiviral Agents